

## SCHEDA DI ISCRIZIONE 5 APRILE 2024

La scheda compilata va inviata entro il 1 aprile 2024 per e-mail a:  
ECM NETWORK - Centro Direzionale Isola E3 - 80143 Napoli -  
Tel. 081.7879520 (int. 4), email: congressi@ecmnetwork.it o può iscriversi  
direttamente sul sito [www.ecmnetwork.it](http://www.ecmnetwork.it).  
L'effettiva iscrizione dovrà essere effettuata in sede congressuale entro le ore  
8.00. Per la certificazione ECM è indispensabile compilare in modo chiaro e  
leggibile sia la Scheda di Iscrizione che il Modulo ECM (in particolare codice  
fiscale ed indirizzo email) poichè l'attestato ECM verrà inviato esclusivamente  
per posta elettronica.

Prof./Dott.

Luogo di nascita

Data di nascita

C.F.

Residente a

C.a.p.

Via

Tel. Fax

E-mail

Tipo di professione  Dipendente  Libero professionista  
 Convenzionato  Privo di occupazione

Istituto di appartenenza

Ai sensi del D.Lgs. 196/2003 sulla tutela dei dati personali si autorizza  
espressamente la ECM NETWORK a trattare le informazioni raccolte ed  
inserite nella sua banca dati, nonchè l'utilizzo delle stesse per finalità  
legate all'attività esercitata.

Data Firma

## Faculty

Gianmarco Abbadesse  
Gennaro Alfieri  
Vincenzo Andreone  
Rossana Arlomedea  
Paolo Barone  
Simona Bonavita  
Vito Campana  
Antonio Carotenuto  
Florindo D'Onofrio  
Gabiella De Joanna  
Antonio De Mase  
Rosa De Micco  
Maria Elena Di Battista  
Walter Di Iorio  
Marcello Esposito  
Alfonso Giordano  
Alessandro Iavarone  
Silvestro La Pia  
Luca Lombardi  
Fiore Manganelli  
Giacchino Martusciello  
Stefania Miniello  
Massimo Napolitano  
Maria Nolano  
Vincenzo Palma  
Marina Picillo  
Giovanni Piccirillo  
Rosaria Renna  
Patrizia Ripa  
Bruno Ronga  
Felice Romano  
Leonardo Sinisi  
Giacchino Tedeschi  
Alessandro Tessitore  
Stefano Tozza

## Con il contributo non condizionante di:



## Responsabili Scientifici

Vincenzo Andreone, Stefania Miniello

## Scientific Committee

Gennaro Alfieri, Antonio De Mase, Walter Di Iorio,  
Andrea Di Pietro, Luca Lombardi, Vincenzo Loreto,  
Giorgia Maniscalco, Giacchino Martusciello, Carlo Maurea,  
Massimo Napolitano, Giovanni Piccirillo, Angelo Ranieri,  
Rosaria Renna, Emanuele Spina

## E.C.M.

Il Workshop è stato accreditato presso il  
Ministero della Salute nell'ambito del programma ECM,  
consentirà pertanto di acquisire crediti formativi

## Riferimenti ECM

Congresso rivolto a:

### Farmacista

(Farmacista Pubblico del SSN; Farmacista Territoriale)

### Fisioterapisti

### Infermieri

### Medico Chirurgo

(Neurologia, Neurofisiopatologia, Reumatologia,  
Medicina Interna, Medicina di accettazione e di urgenza;  
Psichiatria)

### Tecnico Di Neurofisiopatologia

N. ECM 6331-409349

N. 9 ore formative

Crediti 9

## Area Formativa

Acquisizione competenze di processo

Obiettivo formativo N. 3

Documentazione clinica.

Percorsi clinico-assistenziali diagnostici e  
riabilitativi, profili di assistenza - profili di cura

## Provider e Segreteria Organizzativa



Centro Direzionale Isola E3 - 80143 Napoli  
tel. 081.7879520 (int. 4)  
congressi@ecmnetwork.it  
www.ecmnetwork.it

# Update on Opinability Areas in Neurology

April, 5 - 2024

Palazzo Alabardieri  
Napoli

E.C.M.  
Educazione Continua in Medicina



## Programma

**08.00** Participant registration

Greetings of the Authorities and  
Opening the Congress

*A. Annechiarico, A. D'Amore, G. D'Onofrio, G. Gubitosa*

**08.20** Introduction and welcome remarks

*V. Andreone, S. Miniello, B. Ronga*

### I SESSION

#### Parkinson Disease, NeuroOncology and Mood Disorders

Chairmen: *B. Ronga, G. Tedeschi, A. Tessitore,*

*Every speech is preceded by vote*

**09:00** Advanced PD: subcutaneous FOS levodopa /  
carbidopa could be the first choice? YES or NOT  
*M. Picillo*

**09:15** Is it already time to shift from clinical to  
biological diagnosis of PD? YES or NOT  
*R. De Micco*

**09:30** COMT and Mao-B inhibition in early Parkinson  
disease: is it really a good option?  
*W. Di Iorio*

**09:45** The landscape of oncology has changed:  
how long could neurologists still escape from  
neuro oncology?  
*M. Napolitano*

**10:00** Is the serotonin theory of depression still valid?  
YES or NOT  
*S. La Pia*

**10:15** Discussion and Post-Debate Voting

**11.00** Coffee Break

### II SESSION Epilepsy, Headache

Chairmen: *R. Arlomedea, P. Barone, A. Iavarone*

*Every speech is preceded by vote*

**11:30** Is there a limit to the number of drugs suitable  
as adjunctive treatment for drug resistant  
epilepsy? YES or NOT  
*R. Renna*

**11:45** Is it ethical to provoke psychogenic seizures  
for purposes of diagnosis? YES or NOT  
*A. Giordano*

**12:00** Is there an ideal drug to treat both migraine  
and epilepsy? YES or NOT  
*V. Campana*

**12:30** Will oral anti-CGRP drugs displace injectable  
ones in the prevention of migraine? YES or NOT  
*L. Lombardi*

**12:45** How should we consider ditans and gepants?  
First or second choice?  
*G. Alfieri*

**13:00** Do white matter hyperintensities in MRI of  
migraine patients have clinical significance?  
YES or NOT  
*F. D'Onofrio*

**13:15** Discussion and Post-Debate Voting

**13.30** Lunch

### III SESSION Stroke and Multiple Sclerosis

Chairmen: *S. Bonavita, L. Sinisi, G. Martusciello*

*Every speech is preceded by vote*

**14:30** Is there a Loop recorder or an anticoagulant  
treatment for everyone?  
The ESUS saga goes on  
*G. Piccirillo*

**14:45** Carotid MCA tandem occlusion: Stenting or  
PTA?  
*P. Ripa*

**15:00** Low NIHSS stroke with LVO: to treat or not to  
treat?  
*A. De Mase*

**15:15** NMO: should complement inhibitors be  
offered as a second line of treatment?  
YES or NOT  
*M. E. Di Battista*

**15:30** Is PIRA a correct measure of the disease  
progression in multiple sclerosis?  
YES or NOT  
*A. Carotenuto*

**15:45** Is there a role for EBV in MS pathogenesis?  
YES or NOT  
*G. Abbadessa*

**16:00** Disease modifying therapy at any age?  
YES or NOT  
*F. Romano*

**16:15** Discussion and Post-Debate Voting

### IV SESSION Muscle and Nerves

Chairmen: *F. Manganelli, M. Nolano, V. Palma*

*Every speech is preceded by vote*

**16:30** Should diabetes mellitus-associated  
plexopathy be treated with high dose  
corticosteroids? YES or NOT  
*G. De Joanna*

**16:45** Familial amyloid polyneuropathy: should  
neurologist screen for it all the  
polyneuropathies without etiology?  
YES or NOT  
*S. Tozza*

**17:00** Is it always appropriate to treat upper limb  
tremor? YES or NOT  
*M. Esposito*

**18:00** *Highlights of the day. Poll results and  
conclusive remarks*

**18:30-18:50** Learning questionnaire

### Razionale

Few medical specialties have faced such groundbreaking changes in such a short time, as Neurology did, leaving its hazy and somewhat mystical but nihilistic air, turning into a modern, scientific and often treatable medical area. Moreover, general diagnostic and treatment strategies have often given way their way to tailored approaches. Indeed, thanks to the major changes in the diagnosis and treatment of cerebrovascular diseases, particularly in ischemic stroke, the most common neurological disease, nowadays we can halve stroke-related disability. The advent of monoclonal antibodies dramatically changed the quality of life of people suffering from episode and chronic migraines and is about to revolutionize the treatment of dementias. Multiple sclerosis and neuro-immunological CNS and PNS disorders can now benefit from modern diagnostic criteria and innovative care, significantly modifying the course of the diseases. Moreover, new and more tolerable drugs expanded the treatment options for epilepsy and new frontiers are being explored in the management of advanced Parkinson's disease. However... Is it all so clear? Is there enough and robust evidence supporting our everyday clinical decision-making? The aim of this conference is to shed light on many persisting grey areas in Neurology. Experts in specific fields will take turns, giving their point of view, and, whenever possible, trying to solve your doubts in a friendly and captivating discussion.